Simultaneous control of PTH and Ca×P is sustained over three years of treatment with cinacalcet HCl

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue 9, 2009, Pages 1465-1476

  Sprague, Stuart M ^a   Evenepoel, Pieter ^b   Curzi, Mario P ^c   González, Maria Teresa ^d   Husserl, Fred E ^e   Kopyt, Nelson ^f   Sterling, Lulu Ren ^g   Mix, Chris ^g   Wong, Gordon ^h  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c Diablo Nephrology Medical Group   (United States)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e OCHSNER CLINIC FOUNDATION   (United States)

^f Nephrology Hypertension Associates of Lehigh Valley   (United States)

^g AMGEN INC   (United States)

^h CREDIT VALLEY HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CINACALCET; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; PLACEBO; VITAMIN D;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS; HORMONAL REGULATION; HUMAN; HYPOCALCEMIA; HYPOTENSION; KIDNEY FAILURE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPEN STUDY; PERITONEAL DIALYSIS; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM; TETANY; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; BIOLOGICAL MARKERS; CALCIUM; CANADA; CHELATING AGENTS; CHRONIC DISEASE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY DISEASES; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROID HORMONE; PERITONEAL DIALYSIS; PHOSPHATES; PHOSPHORUS; RENAL DIALYSIS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VITAMIN D;

EID: 73049181786     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.06141108     Document Type: Article

References (20)

1. Torres PU: Cinacalcet HCl: A novel treatment for secondary hyperparathyroidism caused by chronic kidney disease. J Ren Nutr 16: 253-258, 2006
2. Chertow GM, Johansen KL, Lew N, Lazarus JM, Lowrie EG: Vintage, nutritional status, and survival in hemodialysis patients. Kidney Int 57: 1176-1181, 2000
3. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31: 607- 617, 1998
4. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK: Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int 67: 1179-1187, 2005
5. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK: Association of elevated serum PO(4), Ca×PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12: 2131-2138, 2001
6. Rostand SG, Drueke TB: Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 56: 383-392, 1999
7. Brown AJ, Slatopolsky E: Drug insight: Vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. Nature Clinical Practice Endocrinology & Metabolism 3(2): 134 -144, 2007
8. 2) in dialysis patients with secondary hyperparathyroidism: A sequential comparison. Am J Kidney Dis 37(3): 532-543, 2001
9. Steddon SJ, Schroeder NJ, Cunningham J: Vitamin D analogues: How do they differ and what is their clinical role? Nephrol Dial Transplant 16: 1965-1967, 2001
10. Moe SM, Drueke TB: Management of secondary hyperparathyroidism: The importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus produce. Am J Nephrol 23: 369-379, 2003
11. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drüeke TB, Goodman WG: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350: 1516-1525, 2004
12. Shahapuni I, Mansour J, Harbouche L, Maouad B, Benyahia M, Rahmouni K, Oprisiu R, Bonne JF, Monge M, El Esper N, Presne C, Moriniere P, Choukroun G, Fournier A: How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients? Semin Dial 18: 226-238, 2005
13. Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD, Albizem MB, Coburn JW: Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study. J Am Soc Nephrol 16: 800-807, 2005
14. Strippoli GF, Palmer S, Tong A, Elder G, Messa P, Craig JC: Meta-analysis of biochemical and patient-level effects of calcimimetic therapy. Am J Kidney Dis 47: 715-726, 2006
15. Moe SM, Cunningham J, Bommer J, Adler S, Rosansky SJ, Urena-Torres P, Albizem MB, Guo MD, Zani VJ, Goodman WG, Sprague SM: Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant 20: 2186-2193, 2005
16. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42: S1-S201, 2003
17. Sterrett JR, Strom J, Stummvoll H-K, Bahner U, Disney A, Soroka SD, Corpier C, Arruda JA, Schwanauer LE, Klassen PS, Olson KA, Block GA: Cinacalcet HCL (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 68: 10-17, 2007
18. Goodman WG, Spiegel DM, Fadda GZ, Lien YH, Zeig S, Finkelstein FO, Mittman N, Olson KA, McMary LC, Klassen PS, Quarles LD: The magnitude of reductions in elevated serum calcium (Ca), Phosphorus (P), and CaxP levels with cinacalcet HCl is influenced by the dose of concurrent vitamin D sretols [Abstract F-PO753]. Am Soc Nephrol 16: 500A, 2005
19. Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, Drüeke TB, Cunningham J, Sherrard DJ, McCary LC, Olson KA, Turner SA, Martin KJ: Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 67: 760-771, 2005
20. Brandi L, Daugaard H, Tvedegaa E, Nielsen PK, Egmose C, Storm T, Olgaard K: Long-term suppression of secondary hyperparathyroidism by intravenous 1alpha-hydroxy vitamin D3 in patients on chronic hemodialysis. Am J Nephrology 12: 311, 1992